Who was studied?
Adults with HIV receiving antiretroviral therapy were randomized to 2 mg daily or placebo; 48 received study treatment.
- Participants
- 50 randomized adults
- Duration
- 6 months
- Funding
- NIH support; Massachusetts General Hospital investigator-led trial
What did the study find?
VAT changed by −34 cm² versus +8 cm² with placebo. Median liver lipid-to-water percentage changed by −2.0 versus +0.9 percentage points.
What should you keep in mind?
This was a small study. Fasting glucose rose early in treatment; long-term clinical significance of the imaging findings remained uncertain.
Why it matters
Different fat compartments require different measurements. This result does not establish treatment benefits in people without HIV.
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
Published 2014 · PMID 25038357 · DOI 10.1001/jama.2014.8334
Summary by Peptide Lit, checked against the original abstract on October 8, 2026. Read the complete paper for detailed methods and safety results. This page explains published research; it does not recommend a treatment or dose.